Protara Therapeutics Past Earnings Performance
Past criteria checks 0/6
Protara Therapeutics's earnings have been declining at an average annual rate of -23%, while the Biotechs industry saw earnings growing at 13.4% annually.
Key information
-23.0%
Earnings growth rate
-3.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -44.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Protara Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -41 | 18 | 27 |
| 31 Mar 24 | 0 | -42 | 18 | 28 |
| 31 Dec 23 | 0 | -40 | 19 | 25 |
| 30 Sep 23 | 0 | -69 | 19 | 24 |
| 30 Jun 23 | 0 | -67 | 19 | 21 |
| 31 Mar 23 | 0 | -64 | 20 | 17 |
| 31 Dec 22 | 0 | -66 | 21 | 17 |
| 30 Sep 22 | 0 | -37 | 22 | 16 |
| 30 Jun 22 | 0 | -40 | 24 | 17 |
| 31 Mar 22 | 0 | -45 | 25 | 19 |
| 31 Dec 21 | 0 | -47 | 26 | 21 |
| 30 Sep 21 | 0 | -46 | 25 | 21 |
| 30 Jun 21 | 0 | -43 | 24 | 19 |
| 31 Mar 21 | 0 | -37 | 22 | 16 |
| 31 Dec 20 | 0 | -34 | 22 | 12 |
| 30 Sep 20 | 0 | -28 | 19 | 9 |
| 30 Jun 20 | 0 | -22 | 15 | 7 |
| 31 Mar 20 | 0 | -16 | 11 | 6 |
| 31 Dec 19 | 0 | -8 | 4 | 4 |
| 30 Sep 19 | 0 | -7 | 2 | 4 |
| 31 Dec 18 | 0 | -4 | 1 | 3 |
Quality Earnings: 1KPA is currently unprofitable.
Growing Profit Margin: 1KPA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1KPA is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare 1KPA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1KPA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 1KPA has a negative Return on Equity (-44.2%), as it is currently unprofitable.